WordNet

restriction imposed by the government on documents or weapons that are available only to certain authorized people
a group of people or things arranged by class or category (同)categorization, categorisation
the basic cognitive process of arranging into classes or categories (同)categorization, categorisation, sorting
the 6th letter of the Roman alphabet (同)f

PrepTutorEJDIC

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/03/10 17:31:54」(JST)

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 急性骨髄性白血病の臨床症状、病理学的特徴、および診断 clinical manifestations pathologic features and diagnosis of acute myeloid leukemia
2. 成人における骨髄異形成症候群の予後 prognosis of the myelodysplastic syndromes in adults
3. 急性骨髄性白血病の予後 prognosis of acute myeloid leukemia
4. 急性骨髄性白血病の病因 pathogenesis of acute myeloid leukemia
5. 骨髄穿刺塗抹標本の評価 evaluation of bone marrow aspirate smears

Teplyakov A1, Gilliland GL.
Proteins.Proteins.2014 Aug;82(8):1668-73. doi: 10.1002/prot.24559. Epub 2014 Apr 16.
Despite sequence diversity, five out of six hypervariable loops in antibodies assume a limited number of conformations called canonical structures. Their correct identification is essential for successful prediction of antibody structure. This in turn requires regular updates of the classification o
PMID 24623659

Ahmadi A1, Poorfathollah AA, Aghaiipour M, Rezaei M, Nikoo-ghoftar M, Abdi M, Gharib A, Amini A.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.Tumour Biol.2014 Jul;35(7):6763-8. doi: 10.1007/s13277-014-1899-8. Epub 2014 Apr 11.
C-kit receptor (CD117) and its ligand, stem cell factor, play a key role in normal hematopoiesis. It has been demonstrated that its expression extremely increases in leukemias with myeloid commitment. We analyzed findings on CD117 expression together with other myeloid related markers in 203 de novo
PMID 24722823

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.

Ehninger A1, Kramer M1, Röllig C1, Thiede C1, Bornhäuser M1, von Bonin M1, Wermke M1, Feldmann A2, Bachmann M2, Ehninger G1, Oelschlägel U1.
Blood cancer journal.Blood Cancer J.2014 Jun 13;4:e218. doi: 10.1038/bcj.2014.39.
Owing to the more recent positive results with the anti-CD33 immunotoxin gemtuzumab ozogamicin, therapy against acute myeloid leukemias (AMLs) targeting CD33 holds many promises. Here, CD33 and CD123 expression on AML blasts was studied by flow cytometry in a cohort of 319 patients with detailed inf
PMID 24927407